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Previewsdisease. So far, most of our knowledge of
NF-kB signaling in liver pathophysiology
is derived from studies in which NF-kB
activation or activity is inhibited. The
authors used the opposite approach
trying to activate NF-kB by removing
CYLD. Surprisingly, only hepatocytes in
close vicinity to the portal triad suffer
spontaneous apoptosis but only after
postnatal day 10, arguing against a cell
autonomous promotion of cell death in
the absence of CYLD. If this is the case,
what triggers the periportal cell death
from postnatal day 10 onward? Perti-
nently, the authors point to commensal
bacteria in the gut. During embryogenesis
and shortly after birth, the gut is sterile and
thus, the portal circulation to the liver is
free of bacteria or microbial products.
However, after the first postnatal days,
the microflora start colonizing the gut,
and an influx of microbial components,
such as lipopolysaccharide (LPS) reaches
the liver. At this point, if the hepatocytes
are devoid of CYLD, an important attenu-
ator of NF-kB signaling, they misinterpret
the amount of LPS and other TLR agonists
to which they are exposed. Invariably,
this would lead to programmed cell death
in hepatocytes that overreact to TLR
agonists. Of note, CYLD is expressed in
a gradient, being higher in the periportal712 Cancer Cell 21, June 12, 2012 ª2012 Elsregion and lower close to the central
vein, supporting an important role for
CYLD in signal fine-tuning in the area
where TLR agonist concentration can
fluctuate the most. New investigations
using germ-free CyldDhep mice would
provide an important test of this hypoth-
esis. After this initial trigger, the CYLD-
deficient liver starts on a self-destruction
spiral. The initial death of periportal hepa-
tocytes triggers an inflammatory re-
sponse mediated by Kupffer cells. These
cells produce TNF and other death cyto-
kines that act on hyper-responsive hepa-
tocytes, causing more cell death and
more inflammation, eventually enhancing
compensatory proliferation. Interestingly,
Dapito et al. (2012) recently reported that
HCC promotion is affected by intestinal
microbiota through TLR4 signaling in the
liver. Considering that in several human
liver diseases there is an increase in intes-
tinal permeability and consequently an
increase of microbial components in the
portal circulation, the studies of Nikolaou
et al. (2012) and Dapito et al. (2012) estab-
lish a new paradigm in liver disease in
which intestinal microbiota can determine
hepatocyte cellular survival and death.
Thus, the intestinal barrier and com-
mensal microflora further influence the
NF-kB-JNK interplay that is alreadyevier Inc.known to play a central role in the control
of liver pathophysiology.REFERENCES
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Data from human tumors and mouse models suggest that tetraploidy, one example of polyploidy, can pro-
mote tumorigenesis. In this issue of Cancer Cell, Davoli and De Lange make important connections between
tetraploidy, tumorigenesis, and telomere crisis—a common event during the development of human cancers.Organism-level polyploidy-increasedcom-
plete sets of chromosomes are very
frequent in plants and are often found ininsects, fish, and amphibians. Genome
doublings are less common in metazoans,
but at least two tetraploidization eventsare thought to have occurred during the
evolution of vertebrates. Although still
debated, it has been proposed that during
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Previewsevolution, the extra chromosomes coming
from a genome doubling could provide
fodder for evolutionary experimentation,
with the extra chromosomes being mu-
tated, broken, and rearranged while via-
bility ismaintainedby the setof intact chro-
mosomes (Otto, 2007).This isanappealing
idea that could be relevant to tumorigen-
esis. Indeed, tetraploid cells lacking the
p53 tumor suppressor, generated by cyto-
kinesis failure, are tumorigenic, and the
resulting tumors display markedly altered
genomes (Fujiwara et al., 2005).
The role of polyploidy in certain cell
lineages during development is inter-
esting but even more poorly understood.
Polyploidy occurs in many metabolically
active cells—hepatocytes, cardiomyo-
cytes, trophoblast giant cells, and retinal
pigment epithelial cells, to name a few
(Davoli and de Lange, 2011). The correla-
tion between polyploidy and metabolic
activity has led to the speculation that
polyploidy might confer a metabolic
benefit, but the nature of this postulated
benefit is entirely mysterious. Perhaps
these poorly understood benefits drive
polyploidization during the development
of some cancers.
Although in special circumstances
polyploidy may confer some benefits, it
is not always a good deal. Newly-
generated tetraploid cells, in organisms
as diverse as yeasts and humans, exhibit
mitotic defects and very high rates of
whole chromosome aneuploidy (Davoli
and de Lange, 2011). In mammals, most
if not all of the chromosomal instability
that accompanies tetraploidy is due to
the presence of extra centrosomes. For
example, it has been possible to isolate
tetraploid cells in vitro that have sponta-
neously lost their extra centrosomes,
and these cells exhibit normal genetic
stability (Ganem et al., 2009). Indeed,
most polyploid cells inmammalian tissues
do not divide or only rarely divide, pre-
sumably because of the genetic instability
that results from cell division of polyploid
cells. When dividing cells do accidentally
become tetraploid, a stress response is
triggered that, with variable penetrance,
can activates p53 and limit cell prolifera-
tion (Margolis et al., 2003).
Even though most mammalian cells are
not programmed to become tetraploid,
tetraploidy can occur as a consequence
of a variety of pathological events. Errors
in DNA replication or mitosis can lead tochromatin trapped in the cleavage furrow,
eventually causing cytokinesis failure and
tetraploidization. After a prolonged mito-
tic arrest, due to the activation of the
spindle checkpoint, cells can undergo
‘‘mitotic slippage’’ and become tetra-
ploid. Tetraploidization may also occur
by cell fusion, for example, induced by
viruses (Davoli and de Lange, 2011).
More recently, a surprising newmecha-
nism to induce tetraploidy was uncov-
ered: the endoreduplication of chromo-
somes (the absence of mitosis between
two rounds of DNA replication) in the
face of a persistent DNA damage signal,
either from unprotected telomeres or
from DNA damaging agents (Davoli
et al., 2010). Deprotected telomeres are
of particular interest because telomeres
have been found to shorten during the
early stages of many epithelial cancers.
When p53-deficient cells suffer persistent
DNA damage, DNA damage response
kinases are activated. Among other
substrates, these kinases phosphorylate
and inactivate the Cdc25 phosphatases,
thus blocking CyclinB/Cdk1 activity and
preventing mitotic entry. However, Davoli
and de Lange (2012), in this issue of
Cancer Cell, found unexpectedly that the
cell cycle does not halt, but rather flips
between the G2 and the G1 phase without
nuclear envelope breakdown or mitosis.
During these endocycles, the origins of
DNA replication are first licensed in G1,
cells then enter S phase and complete
DNA synthesis, but after a period of time
in G2, geminin, a key inhibitor of DNA re-
replication, is eventually degraded, allow-
ing the entire cycle noted above to be
repeated if the cells lack p53 (Davoli
et al., 2010).
The new paper from Davoli and de
Lange (2012) goes more deeply into the
underlyingmechanism and directly estab-
lishes that these events can promote
tumorigenesis. In their previous work,
Davoli and de Lange had induced telo-
mere crisis in mouse cells somewhat arti-
ficially by genetic ablation of Pot1, which
encodes a key protein required for telo-
mere protection (Davoli et al., 2010).
Here, they show that endoreduplica-
tion occurs in cells undergoing a more
‘‘physiological’’ telomere crisis, using
late passage telomerase-negative cells.
In a variety of human cell types, tetra-
ploidization occurs either by endoredu-
plication, as described above, or by cyto-Cancer Cellkinesis failure, with different proportions
of these events observed in different cell
types (Figure 1). The development of large
numbers of tetraploid cells not only
requires loss of p53, but also loss of the
Rb tumor suppressor. Loss of Rb pre-
vents a G1 arrest that would otherwise
be imposed by activation of the CDK
inhibitor p16. Finally, after transiently
inactivating telomere protection in p53-
deficient mouse embryo fibroblasts,
diploid and tetraplopid cells were sepa-
rated by FACS-sorting and tested for
their transforming potential. Satisfyingly,
the tetraploid cells exhibited significantly
greater tumorigenic activity than the
diploid cells carried through the same
isolation procedure. Analysis of tumor
karyotypes showed that the tumor
genomes had evolved a subtetraploid
chromosome content. The generation of
unstable tetraploid cells, followed by
evolution to a subtetraploid genome may
occur in human tumors, as was recently
inferred from genomic analysis of metas-
tases from a renal carcinoma (Gerlinger
et al., 2012).
Altogether, these findings show that
telomere attrition is a double whammy.
It is already known that critical telo-
mere shortening can lead to chromosome
breaks and rearrangements via breakage-
fusion-bridge cycles. The new findings
reveal that tetraploidy adds further fuel
to the fire. Importantly, both sources of
instability are potentially reversible. After
telomere crisis, breakage-fusion-bridge
cycles are short-circuited by reexpression
of telomerase. Likewise, the transformed
tetraploid cells generated by Davoli and
de Lange (2012) evolved to presumably
more stable subtetraploid genomes (Fig-
ure 1). Transient genetic instability may
be beneficial to a developing cancer cell;
it increases the chances of obtaining
transforming mutations but obviates the
need to pay the fitness cost of ongoing
instability.
This work raises a host of interesting
biological and mechanistic questions.
First: if nascent tumor cells go through
a genome doubling, at what point in
tumor development does that occur?
Recent work by Carter et al. (2012) took
a computational approach to analyze
DNA copy number data from a huge
number of tumors. This study confirms
that genome doublings and near-tetra-
ploid genomes are remarkably common.21, June 12, 2012 ª2012 Elsevier Inc. 713
Figure 1. Telomere Dysfunction Promotes Tetraploidy
(A) Endoreduplication after prolonged DNA damage of p53 deficient cells. Telomere dysfunction, or other persistent DNA damage, generates a DNA damage
response that arrests p53 deficient cells in theG2 phase of the cell cycle. After a prolonged arrest, diploid (2N) cells degrade the DNA replication inhibitor geminin,
license DNA replication origins, and start a new round of DNA synthesis without enteringmitosis. The resultant tetraploid cells survive and proliferate if telomerase
is re-expressed. This tetraploid clone can promote tumorigenesis and often evolves to a subtetraploid karyotype.
(B) Tetraploidization after cytokinesis failure. In the setting of deprotected telomeres, cells can develop telomere end-to-end fusions. This generates dicentric
chromosomes and initiates chromosome breakage-fusion-bridge cycles. The dicentric chromosomes generated by this mechanism can result in chromatin trap-
ped at the cleavage furrow and subsequent failure of cytokinesis. Both mechanisms of tetraploidization result in centrosome amplification and additional chro-
mosomal instability.
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PreviewsHowever, their data suggest that genome
doublings often occur relatively late, after
the acquisition of other chromosome
aneuploidies. This is perhaps not that
surprising given the need for p53 loss
to enable the proliferation of polyploid
cells. Also, polyploidy need not always
be integral to tumor development; in
some circumstances, it may be con-
sequence rather than cause. Second:
what is the mechanism by which poly-
ploidy accelerates oncogenesis? Recent
work has revealed that errors in mitotis
can cause DNA damage and thus poten-
tially produce cancer-causing mutations
(Crasta et al., 2012; Janssen et al.,
2011). Given that centrosome ampli-
fication is instrumental in driving the
instability of tetraploid cells (Ganem714 Cancer Cell 21, June 12, 2012 ª2012 Elset al., 2009), a parsimonious hypothesis
is that genome doublings may drive
tumor development in the old-fashioned
way—by generating mutations that acti-
vate oncogenes and inactivate tumor
suppressors.REFERENCES
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